{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:37:07Z","timestamp":1791423427463,"version":"4.3.3"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,10,1]]},"DOI":"10.1093\/jac\/dki291","type":"journal-article","created":{"date-parts":[[2005,8,24]],"date-time":"2005-08-24T20:13:23Z","timestamp":1124914403000},"page":"611-614","source":"Crossref","is-referenced-by-count":196,"title":["Tigecycline: what is it, and where should it be used?"],"prefix":"10.1093","volume":"56","author":[{"given":"David M.","family":"Livermore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2005,8,24]]},"reference":[{"key":"key\n\t\t\t\t20171010182531_B1","doi-asserted-by":"crossref","unstructured":"Milatovic D, Schmitz FJ, Verhoef J et al. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob Agents Chemother2003; 47: 400\u20134.","DOI":"10.1128\/AAC.47.1.400-404.2003"},{"key":"key\n\t\t\t\t20171010182531_B2","doi-asserted-by":"crossref","unstructured":"Fritsche TR, Kirby JT, Jones RN. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and Gram-positive cutaneous infections. Diagn Microbiol Infect Dis2004; 49: 201\u20139.","DOI":"10.1016\/j.diagmicrobio.2004.03.002"},{"key":"key\n\t\t\t\t20171010182531_B3","doi-asserted-by":"crossref","unstructured":"Henwood CJ, Gatward T, Warner M et al. Antibiotic resistance among clinical isolates of Acinetobacter in the United Kingdom and in-vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother2002; 49: 479\u201387.","DOI":"10.1093\/jac\/49.3.479"},{"key":"key\n\t\t\t\t20171010182531_B4","doi-asserted-by":"crossref","unstructured":"Pachon-Ibanez ME, Jimenez-Mejias ME, Pichardo C et al. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother2004; 48: 4479\u201381.","DOI":"10.1128\/AAC.48.11.4479-4481.2004"},{"key":"key\n\t\t\t\t20171010182531_B5","unstructured":"Olivia ME, Rekha A, Yellin A et al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem\/cilastatin in patients with complicated intra-abdominal infections. BMC Surg2005; in press."},{"key":"key\n\t\t\t\t20171010182531_B6","doi-asserted-by":"crossref","unstructured":"Fomin P, Beuran M, Gradauskas A et al. Tigecycline is efficacious in the treatment of complicated intra-abdominal infections. Int J Surg2005; 3: 35\u201347.","DOI":"10.1016\/j.ijsu.2005.03.011"},{"key":"key\n\t\t\t\t20171010182531_B7","doi-asserted-by":"crossref","unstructured":"Sacchidanad S, Penn RL, Embil JM et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a Phase 3, randomized, double-blind trial. Int J Infect Dis2005; (16 August 2005, published online).","DOI":"10.1016\/j.ijid.2005.05.003"},{"key":"key\n\t\t\t\t20171010182531_B8","doi-asserted-by":"crossref","unstructured":"Breedt J, Teras J, Gardovskis J et al. The safety and efficacy of tigecycline in the treatment of skin and skin structure infections: results of a double-blind Phase 3 comparison study with vancomycin\/aztreonam. Antimicrob Agents Chemother2005; in press.","DOI":"10.1128\/AAC.49.11.4658-4666.2005"},{"key":"key\n\t\t\t\t20171010182531_B9","doi-asserted-by":"crossref","unstructured":"Testa RT, Petersen PJ, Jacobus NV et al. In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines. Antimicrob Agents Chemother1993; 37: 2270\u20137.","DOI":"10.1128\/AAC.37.11.2270"},{"key":"key\n\t\t\t\t20171010182531_B10","doi-asserted-by":"crossref","unstructured":"Sum PE, Petersen P. Synthesis and structure\u2013activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. Bioorg Med Chem Lett1999; 9: 1459\u201362.","DOI":"10.1016\/S0960-894X(99)00216-4"},{"key":"key\n\t\t\t\t20171010182531_B11","doi-asserted-by":"crossref","unstructured":"Petersen PJ, Jacobus NV, Weiss WJ et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother1999; 43: 738\u201344.","DOI":"10.1128\/AAC.43.4.738"},{"key":"key\n\t\t\t\t20171010182531_B12","doi-asserted-by":"crossref","unstructured":"Fluit AC, Florijn A, Verhoef J et al. Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline. Antimicrob Agents Chemother2005; 49: 1636\u20138.","DOI":"10.1128\/AAC.49.4.1636-1638.2005"},{"key":"key\n\t\t\t\t20171010182531_B13","doi-asserted-by":"crossref","unstructured":"Chopra I. Genetic and biochemical basis of tetracycline resistance. J Antimicrob Chemother1986; 18 (Suppl C): 51\u20136.","DOI":"10.1093\/jac\/18.Supplement_C.51"},{"key":"key\n\t\t\t\t20171010182531_B14","doi-asserted-by":"crossref","unstructured":"Bauer G, Berens C, Projan SJ et al. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate anddrug-directed Fe2+ cleavage of 16S rRNA. J Antimicrob Chemother2004; 53: 592\u20139.","DOI":"10.1093\/jac\/dkh125"},{"key":"key\n\t\t\t\t20171010182531_B15","doi-asserted-by":"crossref","unstructured":"Ruzin A, Keeney D, Bradford PA. AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii. Antimicrob Agents Chemother2005; 49: 791\u20133.","DOI":"10.1128\/AAC.49.2.791-793.2005"},{"key":"key\n\t\t\t\t20171010182531_B16","doi-asserted-by":"crossref","unstructured":"Dean CR, Visalli MA, Projan SJ et al. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother2003; 47: 972\u20138.","DOI":"10.1128\/AAC.47.3.972-978.2003"},{"key":"key\n\t\t\t\t20171010182531_B17","doi-asserted-by":"crossref","unstructured":"Yang W, Moore IF, Koteva KP et al. TetX is a flavin-dependent monooxygenase conferring resistance to tetracycline antibiotics. J Biol Chem2004; 279: 52346\u201352.","DOI":"10.1074\/jbc.M409573200"},{"key":"key\n\t\t\t\t20171010182531_B18","doi-asserted-by":"crossref","unstructured":"Reynolds R, Potz N, Colman M et al. Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001\u20132002: the BSAC Bacteraemia Resistance Surveillance Programme. J Antimicrob Chemother2004; 53: 1018\u201332.","DOI":"10.1093\/jac\/dkh232"},{"key":"key\n\t\t\t\t20171010182531_B19","doi-asserted-by":"crossref","unstructured":"Jacobus NV, McDermott LA, Ruthazer R et al. In vitro activities of tigecycline against the Bacteroides fragilis group. Antimicrob Agents Chemother2004; 48: 1034\u20136.","DOI":"10.1128\/AAC.48.3.1034-1036.2004"},{"key":"key\n\t\t\t\t20171010182531_B20","unstructured":"Hope R, Warner M, Ward ME. Effect of medium type, age and aeration on the MICs of tigecycline and other tetracyclines. Clin Microbiol Infect2005; 11 Suppl 2: 246."},{"key":"key\n\t\t\t\t20171010182531_B21","doi-asserted-by":"crossref","unstructured":"Muralidharan G, Micalizzi M, Speth J et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother2005; 49: 220\u20139.","DOI":"10.1128\/AAC.49.1.220-229.2005"},{"key":"key\n\t\t\t\t20171010182531_B22","doi-asserted-by":"crossref","unstructured":"Postier RG, Green SL, Klein SR et al. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther2004; 26: 704\u201314.","DOI":"10.1016\/S0149-2918(04)90070-7"},{"key":"key\n\t\t\t\t20171010182531_B23","unstructured":"Nosocomial Infection National Surveillance Service. Surveillance of Surgical-Site Infection in English Hospitals 1997\u20132001. Health Protection Agency, 2002. http:\/\/www.hpa.org.uk\/infections\/publications\/ninns\/NINSS-SSI2000.pdf (20 May 2005, date last accessed)."},{"key":"key\n\t\t\t\t20171010182531_B24","doi-asserted-by":"crossref","unstructured":"Woodford N, Ward ME, Kaufmann ME et al. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum\u03b2-lactamases in the UK. J Antimicrob Chemother2004; 54: 735\u201343.","DOI":"10.1093\/jac\/dkh424"},{"key":"key\n\t\t\t\t20171010182531_B25","doi-asserted-by":"crossref","unstructured":"Munday CJ, Whitehead GM, Todd NJ et al. Predominance and genetic diversity of community- and hospital-acquired CTX-M extended-spectrum \u03b2-lactamases in York, UK. J Antimicrob Chemother2004; 54: 628\u201333.","DOI":"10.1093\/jac\/dkh397"},{"key":"key\n\t\t\t\t20171010182531_B26","unstructured":"Livermore DM, Hawkey PM. CTX-M: changing the face of ESBLs in the UK. J Antimicrob Chemother2005; (8 July 2005, published online)."},{"key":"key\n\t\t\t\t20171010182531_B27","doi-asserted-by":"crossref","unstructured":"Livermore DM. Threat from the pink corner. Ann Med2003; 35: 226\u201334.","DOI":"10.1080\/07853890310001609"},{"key":"key\n\t\t\t\t20171010182531_B28","doi-asserted-by":"crossref","unstructured":"Coelho J, Woodford N, Turton J et al. Multiresistant Acinetobacter in the UK: how big a threat? J Hosp Infect2004; 58: 167\u20139.","DOI":"10.1016\/j.jhin.2003.12.019"},{"key":"key\n\t\t\t\t20171010182531_B29","unstructured":"Wilson P. Endemic, highly resistant Acinetobacter in the intensive care unit\u2014is tigecycline the answer? In: Abstracts of the 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, Czech Republic. Abstract P938. Clin Microbiol Infect2004; 10 Suppl 3: 247."},{"key":"key\n\t\t\t\t20171010182531_B30","doi-asserted-by":"crossref","unstructured":"Wood GC, Hanes SD, Boucher BA et al. Tetracyclines for treating multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia. Intensive Care Med2003; 29: 2072\u20136.","DOI":"10.1007\/s00134-003-1811-2"},{"key":"key\n\t\t\t\t20171010182531_B31","doi-asserted-by":"crossref","unstructured":"Weigelt J, Kaafarani HM, Itani KM et al. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am J Surg2004; 188: 760\u20136.","DOI":"10.1016\/j.amjsurg.2004.08.045"},{"key":"key\n\t\t\t\t20171010182531_B32","doi-asserted-by":"crossref","unstructured":"Wunderink RG, Rello J, Cammarata SK et al. Linezolid vs. vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest2003; 124: 1789\u201397.","DOI":"10.1016\/S0012-3692(15)33412-7"},{"key":"key\n\t\t\t\t20171010182531_B33","doi-asserted-by":"crossref","unstructured":"Tuckman M, Petersen PJ, Projan SJ. Mutations in the interdomain loop region of the tetA(A) tetracycline resistance gene increase efflux of minocycline and glycylcyclines. Microb Drug Resist2000; 6: 277\u201382.","DOI":"10.1089\/mdr.2000.6.277"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/56\/4\/611\/2307962\/dki291.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T01:47:21Z","timestamp":1586396841000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/56\/4\/611\/769325\/Tigecycline-what-is-it-and-where-should-it-be-used"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,24]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2005,8,24]]},"published-print":{"date-parts":[[2005,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dki291","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,10]]},"published":{"date-parts":[[2005,8,24]]}}}